Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

  • 1.

    LymanGHKudererNM. Epidemiology of febrile neutropenia. Support Cancer Ther2003;1:2335.

  • 2.

    DaleDC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs2002;62(Suppl 1):115.

  • 3.

    FortnerBVSchwartzbergLTauerK. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer2005;13:522528.

    • Search Google Scholar
    • Export Citation
  • 4.

    DaleDCMcCarterGCCrawfordJLymanGH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw2003;1:440454.

    • Search Google Scholar
    • Export Citation
  • 5.

    US Food and Drug Administration. FDA Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee Advisory Committee Briefing Materials: Available for public release. Tbo-filgrastim. 2013. Accessed July 28 2016.

    • Search Google Scholar
    • Export Citation
  • 6.

    HirschBRLymanGH. Will biosimilars gain momentum?J Natl Compr Canc Netw2013;11:12911297.

  • 7.

    Food and Drug Administration. Tbo-filgrastim [prescribing information]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125294s0000lbl.pdf. Accessed July 28 2016.

    • Search Google Scholar
    • Export Citation
  • 8.

    FareseAMCohenMVKatzBP. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res2013;179:89100.

  • 9.

    SourgensHLefrereF. A systematic review of available clinical evidence—filgrastim compared with lenograstim. Int J Clin Pharmacol Ther2011;49:510518.

    • Search Google Scholar
    • Export Citation
  • 10.

    DorrRT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther1993;15:1929; discussion 18.

    • Search Google Scholar
    • Export Citation
  • 11.

    MooreDC. Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia. P T2016;41:765768.

  • 12.

    LymanGHLymanCHAgboolaO. Risk models for predicting chemotherapy-induced neutropenia. Oncologist2005;10:427437.

  • 13.

    AslaniASmithRCAllenBJ. The predictive value of body protein for chemotherapy-induced toxicity. Cancer2000;88:796803.

  • 14.

    ChrischillesEDelgadoDJStolshekBS. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control2002;9:203211.

    • Search Google Scholar
    • Export Citation
  • 15.

    LymanGHDaleDCFriedbergJ. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol2004;22:43024311.

    • Search Google Scholar
    • Export Citation
  • 16.

    LymanGHDelgadoDJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer2003;98:24022409.

    • Search Google Scholar
    • Export Citation
  • 17.

    LymanGHMorrisonVADaleDC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma2003;44:20692076.

    • Search Google Scholar
    • Export Citation
  • 18.

    MorrisonVAPicozziVScottS. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma2001;2:4756.

    • Search Google Scholar
    • Export Citation
  • 19.

    LymanGHKudererNMCrawfordJ. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer2011;117:19171927.

    • Search Google Scholar
    • Export Citation
  • 20.

    SmithTJBohlkeKLymanGH. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol2015;33:31993212.

    • Search Google Scholar
    • Export Citation
  • 21.

    AaproMSBohliusJCameronDA. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer2011;47:832.

    • Search Google Scholar
    • Export Citation
  • 22.

    VogelCLWojtukiewiczMZCarrollRR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol2005;23:1178-1184.

    • Search Google Scholar
    • Export Citation
  • 23.

    Timmer-BonteJNde BooTMSmitHJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol2005;23:79747984.

    • Search Google Scholar
    • Export Citation
  • 24.

    CrawfordJDaleDCLymanGH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer2004;100:228237.

    • Search Google Scholar
    • Export Citation
  • 25.

    LymanGHKudererNM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 26.

    LymanGH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park)2003;17:813.

  • 27.

    WeyckerDLiXTzivelekisS. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer2017;25:439447.

    • Search Google Scholar
    • Export Citation
  • 28.

    Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2016.

  • 29.

    MeropolNJMillerLLKornEL. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst1992;84:12011203.

    • Search Google Scholar
    • Export Citation
  • 30.

    RowinskyEKGrochowLBSartoriusSE. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol1996;14:12241235.

    • Search Google Scholar
    • Export Citation
  • 31.

    KaufmanPAParolyWRinaldiD. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat2004;88:S59.

    • Search Google Scholar
    • Export Citation
  • 32.

    SavenASchwartzbergLKaywinP. Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 7570.

    • Search Google Scholar
    • Export Citation
  • 33.

    VanceKTCarpenterJ. Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 671.

    • Search Google Scholar
    • Export Citation
  • 34.

    HoffmannPS. Administration of pegfilgrastim on the same day or next day of chemotherapy [abstract]. J Clin Oncol2005;23(Suppl 16):Abstract 8137.

    • Search Google Scholar
    • Export Citation
  • 35.

    BelaniCPRamalingamSAl-JanadiA. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 7110.

    • Search Google Scholar
    • Export Citation
  • 36.

    LokichJ. Same-day pegfilgrastim and chemotherapy. Cancer Invest2005;23:573576.

  • 37.

    SchumanSILambrouNRobsonK. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol2009;7:225228.

    • Search Google Scholar
    • Export Citation
  • 38.

    WhitworthJMMatthewsKSShipmanKA. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol2009;112:601604.

    • Search Google Scholar
    • Export Citation
  • 39.

    Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2015.

  • 40.

    American Society of Clinical Oncology. Letter to CMS regarding “Neulasta administered same day as chemotherapy.”2012. Available at: http://www.wsmos.org/assets/Letter%20to%20CMS%20RAC%20Audit%20on%20Neulasta%20110912%20lthd.pdf. Accessed July 28 2016.

    • Search Google Scholar
    • Export Citation
  • 41.

    YangBBMorrowPKWuX. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol2015;75:11991206.

    • Search Google Scholar
    • Export Citation
  • 42.

    GreenMDKoelblHBaselgaJ. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol2003;14:2935.

    • Search Google Scholar
    • Export Citation
  • 43.

    WatanabeTTobinaiKShibataT. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol2011;29:39903998.

    • Search Google Scholar
    • Export Citation
  • 44.

    HechtJRPillaiMGollardR. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer2010;9:95101.

    • Search Google Scholar
    • Export Citation
  • 45.

    BrusamolinoERusconiCMontalbettiL. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica2006;91:496502.

    • Search Google Scholar
    • Export Citation
  • 46.

    BursteinHJParkerLMKeshaviahA. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol2005;23:83408347.

    • Search Google Scholar
    • Export Citation
  • 47.

    JonesRLWalshGAshleyS. A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer2009;100:305310.

    • Search Google Scholar
    • Export Citation
  • 48.

    PirkerRUlspergerEMessnerJ. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung2006;184:279285.

    • Search Google Scholar
    • Export Citation
  • 49.

    GisselbrechtCHaiounCLepageE. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma1997;25:289300.

    • Search Google Scholar
    • Export Citation
  • 50.

    Trillet-LenoirVGreenJManegoldC. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer1993;29A:319324.

    • Search Google Scholar
    • Export Citation
  • 51.

    BuiBNChevallierBChevreauC. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol1995;13:26292636.

    • Search Google Scholar
    • Export Citation
  • 52.

    ChevallierBCholletPMerroucheY. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol1995;13:15641571.

    • Search Google Scholar
    • Export Citation
  • 53.

    CrawfordJOzerHStollerR. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 54.

    GatzemeierUKleisbauerJPDringsP. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol2000;23:393400.

    • Search Google Scholar
    • Export Citation
  • 55.

    MuhonenTJantunenIPertovaaraH. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol1996;19:232234.

    • Search Google Scholar
    • Export Citation
  • 56.

    OsbyEHagbergHKvaloyS. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood2003;101:38403848.

    • Search Google Scholar
    • Export Citation
  • 57.

    PettengellRGurneyHRadfordJA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood1992;80:14301436.

    • Search Google Scholar
    • Export Citation
  • 58.

    ZinzaniPLPavoneEStortiS. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood1997;89:39743979.

    • Search Google Scholar
    • Export Citation
  • 59.

    BurdachSEMuschenichMJosephsW. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer1995;76:510516.

    • Search Google Scholar
    • Export Citation
  • 60.

    EguchiKKabeJKudoS. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol1994;34:3743.

    • Search Google Scholar
    • Export Citation
  • 61.

    JonesSESchottstaedtMWDuncanLA. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol1996;14:29762983.

    • Search Google Scholar
    • Export Citation
  • 62.

    ArnbergHLetochaHNouF. GM-CSF in chemotherapy-induced febrile neutropenia—a double-blind randomized study. Anticancer Res1998;18:12551260.

    • Search Google Scholar
    • Export Citation
  • 63.

    GerhartzHHEngelhardMMeusersP. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood1993;82:23292339.

    • Search Google Scholar
    • Export Citation
  • 64.

    RoweJMAndersenJWMazzaJJ. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood1995;86:457462.

    • Search Google Scholar
    • Export Citation
  • 65.

    DoorduijnJKvan der HoltBvan ImhoffGW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol2003;21:30413050.

    • Search Google Scholar
    • Export Citation
  • 66.

    FossaSDKayeSBMeadGM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol1998;16:716724.

    • Search Google Scholar
    • Export Citation
  • 67.

    CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 68.

    PfreundschuhMTrumperLKloessM. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 69.

    GutierrezMChabnerBAPearsonD. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol2000;18:36333642.

    • Search Google Scholar
    • Export Citation
  • 70.

    BohliusJHerbstCReiserM. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev2008:CD003189.

    • Search Google Scholar
    • Export Citation
  • 71.

    SungLNathanPCAlibhaiSM. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med2007;147:400411.

    • Search Google Scholar
    • Export Citation
  • 72.

    ClarkOALymanGHCastroAA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol2005;23:41984214.

    • Search Google Scholar
    • Export Citation
  • 73.

    MhaskarRClarkOALymanG. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev2014:CD003039.

    • Search Google Scholar
    • Export Citation
  • 74.

    KudererNMDaleDCCrawfordJLymanGH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol2007;25:31583167.

    • Search Google Scholar
    • Export Citation
  • 75.

    LymanGHDaleDCWolffDA. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol2010;28:29142924.

    • Search Google Scholar
    • Export Citation
  • 76.

    del GiglioAEniuAGanea-MotanD. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer2008;8:332.

    • Search Google Scholar
    • Export Citation
  • 77.

    EngertAGriskeviciusLZyuzginY. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma2009;50:374379.

    • Search Google Scholar
    • Export Citation
  • 78.

    GatzemeierUCiuleanuTDediuM. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol2009;4:736740.

    • Search Google Scholar
    • Export Citation
  • 79.

    EngertAdel GiglioABiasP. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie2009;32:599604.

    • Search Google Scholar
    • Export Citation
  • 80.

    LubenauHBiasPMalyAK. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs2009;23:4351.

    • Search Google Scholar
    • Export Citation
  • 81.

    LubenauHSveikataAGumbreviciusG. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther2009;47:275282.

    • Search Google Scholar
    • Export Citation
  • 82.

    Food and Drug Administration. Filgrastim label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103353s5188.pdf. Accessed August 22 2017.

    • Search Google Scholar
    • Export Citation
  • 83.

    Food and Drug Administration. Pegfilgrastim label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125031s184lbl.pdf. Accessed August 22 2017.

    • Search Google Scholar
    • Export Citation
  • 84.

    BennettCLDjulbegovicBNorrisLBArmitageJO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med2013;368:11311139.

    • Search Google Scholar
    • Export Citation
  • 85.

    KirshnerJJHecklerCEJanelsinsMC. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol2012;30:19741979.

    • Search Google Scholar
    • Export Citation
  • 86.

    KubistaEGlaspyJHolmesFA. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer2003;3:391398.

    • Search Google Scholar
    • Export Citation
  • 87.

    HeilGHoelzerDSanzMA. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood1997;90:47104718.

    • Search Google Scholar
    • Export Citation
  • 88.

    KroschinskyFHoligKEhningerG. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci2008;38:237244.

    • Search Google Scholar
    • Export Citation
  • 89.

    KudererNMDaleDCCrawfordJ. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006;106:22582266.

    • Search Google Scholar
    • Export Citation
  • 90.

    TigueCCMcKoyJMEvensAM. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant2007;40:185192.

    • Search Google Scholar
    • Export Citation
  • 91.

    AkyolGPalaCYildirimA. A rare but severe complication of filgrastim in a healthy donor: splenic rupture. Transfus Apher Sci2014;50:5355.

    • Search Google Scholar
    • Export Citation
  • 92.

    FunesCGarcia-CandelFMajadoMJ. Splenic rupture in a plasma cell leukemia, mobilized with G-CSF for autologous stem cell transplant. J Clin Apher2010;25:223225.

    • Search Google Scholar
    • Export Citation
  • 93.

    O'MalleyDPWhalenMBanksPM. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol2003;73:294295.

    • Search Google Scholar
    • Export Citation
  • 94.

    VeerappanRMorrisonMWilliamsSVariakojisD. Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant2007;40:361364.

    • Search Google Scholar
    • Export Citation
  • 95.

    WatringNJWagnerTWStarkJJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med2007;25:247248.

    • Search Google Scholar
    • Export Citation
  • 96.

    D'SouzaAJaiyesimiITrainorLVenuturumiliP. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev2008;22:280290.

    • Search Google Scholar
    • Export Citation
  • 97.

    AdlerBKSalzmanDECarabasiMH. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood2001;97:33133314.

    • Search Google Scholar
    • Export Citation
  • 98.

    GriggAP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood2001;97:39983999.

    • Search Google Scholar
    • Export Citation
  • 99.

    KangEMAremanEMDavid-OcampoV. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood2002;99:850855.

    • Search Google Scholar
    • Export Citation
  • 100.

    GertzMALacyMQBjornssonJLitzowMR. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res2000;9:635643.

    • Search Google Scholar
    • Export Citation
  • 101.

    BashirQLangfordLAParmarS. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol2011;29:e7980.

    • Search Google Scholar
    • Export Citation
  • 102.

    MartinWGRistowKMHabermannTM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol2005;23:76147620.

    • Search Google Scholar
    • Export Citation
  • 103.

    AzoulayEAttalahHHarfA. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest2001;120:16951701.

    • Search Google Scholar
    • Export Citation
  • 104.

    EvensAMCilleyJOrtizT. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol2007;137:545552.

    • Search Google Scholar
    • Export Citation
  • 105.

    BoletiEMeadGM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol2007;18:376380.

    • Search Google Scholar
    • Export Citation
  • 106.

    HerrmannFSchulzGLindemannA. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study. Behring Inst Mitt1988:107118.

    • Search Google Scholar
    • Export Citation
  • 107.

    SternACJonesTC. The side-effect profile of GM-CSF. Infection1992;20(Suppl 2):S124127.

  • 108.

    Food and Drug Administration. Sargramostim label information. Accessed July 28 2016.

  • 109.

    AmatoRJHernandez-McClainJHenaryH. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate. Urol Oncol2009;27:813.

    • Search Google Scholar
    • Export Citation
  • 110.

    WinerESMillerKBChanGW. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Oncology (Williston Park)2005;19:1114.

    • Search Google Scholar
    • Export Citation
  • 111.

    ArningMKlicheKOSchneiderW. GM-CSF therapy and capillary-leak syndrome. Ann Hematol1991;62:8383.

  • 112.

    Al-HomaidhiAPrinceHMAl-ZahraniH. Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: two case reports and a review of the literature. Bone Marrow Transplant1998;21:209214.

    • Search Google Scholar
    • Export Citation
  • 113.

    EmmingerWEmminger-SchmidmeierWPetersC. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut1990;61:219221.

    • Search Google Scholar
    • Export Citation
  • 114.

    DeerenDHZacheePMalbrainML. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol2005;84:8994.

    • Search Google Scholar
    • Export Citation
  • 115.

    VialTDescotesJ. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf1995;13:371406.

  • 116.

    RellingMVBoyettJMBlancoJG. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood2003;101:38623867.

    • Search Google Scholar
    • Export Citation
  • 117.

    SmithREBryantJDeCillisA. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol2003;21:11951204.

    • Search Google Scholar
    • Export Citation
  • 118.

    HershmanDNeugutAIJacobsonJS. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst2007;99:196205.

    • Search Google Scholar
    • Export Citation
  • 119.

    CoslerLEEldar-LissaiACulakovaE. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics2007;25:343351.

    • Search Google Scholar
    • Export Citation
  • 120.

    DoorduijnJKBuijtIvan der HoltB. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica2004;89:11091117.

    • Search Google Scholar
    • Export Citation
  • 121.

    Eldar-LissaiACoslerLECulakovaELymanGH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health2008;11:172179.

    • Search Google Scholar
    • Export Citation
  • 122.

    NumnumTMKimballKJRocconiRP. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis. Int J Gynecol Cancer2007;17:10191024.

    • Search Google Scholar
    • Export Citation
  • 123.

    Timmer-BonteJNAdangEMTermeerE. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol2008;26:290296.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 2120 2119 224
PDF Downloads 605 605 48
EPUB Downloads 0 0 0